Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of durvalumab ± tremelimumab vs standard of care in first-line recurrent or metastatic squamous cell head and neck cancer
jRCT2080223053Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC), Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC) and 2 more comparing Durvalumab monotherapy, Durvalumab + tremelimumab combination and Standard-of-care chemotherapy (3 arms). Started Dec 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on jRCT2080223053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223053.